|
1
|
Colombo N: Optimizing treatment of the
partially platinum-sensitive ovarian cancer patient. Future Oncol.
9 12 Suppl:S19–S23. 2013. View Article : Google Scholar
|
|
2
|
Friedlander M, Trimble E, Tinker A,
Alberts D, Avall-Lundqvist E, Brady M, Harter P, Pignata S,
Pujade-Lauraine E, Sehouli J, et al: Clinical trials in recurrent
ovarian cancer. Int J Gynecol Cancer. 21:771–775. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
González-Martín A: Update on relapsed
ovarian cancer treatment: From new consensus to daily clinical
practice. Future Oncol. 13(23s): 1–9. 2017. View Article : Google Scholar
|
|
4
|
Gore ME, Fryatt I, Wiltshaw E and Dawson
T: Treatment of relapsed carcinoma of the ovary with cisplatin or
carboplatin following initial treatment with these compounds.
Gynecol Oncol. 36:207–211. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Markman M, Rothman R, Hakes T, Reichman B,
Hoskins W, Rubin S, Jones W, Almadrones L and Lewis JL Jr:
Second-line platinum therapy in patients with ovarian cancer
previously treated with cisplatin. J Clin Oncol. 9:389–393. 1991.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
López-Guerrero JA, Romero I and Poveda A:
Trabectedin therapy as an emerging treatment strategy for recurrent
platinum-sensitive ovarian cancer. Chin J Cancer. 34:41–49. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
González-Martín A and du Bois A: Factors
to consider and questions to ask in the management of recurrent
ovarian cancer: A focus on the role of trabectedin + pegylated
liposomal doxorubicin. Expert Rev Anticancer Ther. 16 Sup1:S3–S10.
2016. View Article : Google Scholar
|
|
8
|
D'Incalci M and Galmarini CM: A review of
trabectedin (ET-743): A unique mechanism of action. Mol Cancer
Ther. 9:2157–2163. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Guirouilh-Barbat J, Redon C and Pommier Y:
Transcription-coupled DNA double-strand breaks are mediated via the
nucleotide excision repair and the Mre11-Rad50-Nbs1 complex. Mol
Biol Cell. 19:3969–3981. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Allavena P, Signorelli M, Chieppa M, Erba
E, Bianchi G, Marchesi F, Olimpio CO, Bonardi C, Garbi A, Lissoni
A, et al: Anti-inflammatory properties of the novel antitumor agent
yondelis (trabectedin): Inhibition of macrophage differentiation
and cytokine production. Cancer Res. 65:2964–2971. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Monk BJ, Herzog TJ, Kaye SB, Krasner CN,
Vermorken JB, Muggia FM, Pujade-Lauraine E, Lisyanskaya AS, Makhson
AN, Rolski J, et al: Trabectedin plus pegylated liposomal
Doxorubicin in recurrent ovarian cancer. J Clin Oncol.
28:3107–3114. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Poveda A, Vergote I, Tjulandin S, Kong B,
Roy M, Chan S, Filipczyk-Cisarz E, Hagberg H, Kaye SB, Colombo N,
et al: Trabectedin plus pegylated liposomal doxorubicin in relapsed
ovarian cancer: Outcomes in the partially platinum-sensitive
(platinum-free interval 6–12 months) subpopulation of OVA-301 phase
III randomized trial. Ann Oncol. 22:39–48. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kaye SB, Colombo N, Monk BJ, Tjulandin S,
Kong B, Roy M, Chan S, Filipczyk-Cisarz E, Hagberg H, Vergote I, et
al: Trabectedin plus pegylated liposomal doxorubicin in relapsed
ovarian cancer delays third-line chemotherapy and prolongs the
platinum-free interval. Ann Oncol. 22:49–58. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Monk BJ, Herzog TJ, Kaye SB, Krasner CN,
Vermorken JB, Muggia FM, Pujade-Lauraine E, Park YC, Parekh TV and
Poveda AM: Trabectedin plus pegylated liposomal doxorubicin (PLD)
versus PLD in recurrent ovarian cancer: Overall survival analysis.
Eur J Cancer. 48:2361–2368. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Colombo N: Optimising the treatment of the
partially platinum-sensitive relapsed ovarian cancer patient. EJC
Suppl. 12:7–12. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Moriceau G, Rivoirard R, Méry B, Vallard
A, Pacaut C, Trone JC, Espenel S, Bosacki C, Jacquin JP and Magné
N: Real-world outcomes of combination chemotherapy with trabectedin
plus pegylated liposomal doxorubicin in patients with recurrent
ovarian cancer: a single-center experience. Chemotherapy.
61:122–126. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Tahir S: Real-life experience using
trabectedin plus pegylated liposomal doxorubicin combination to
treat patients with relapsed ovarian cancer. EJC Suppl. 12:17–20.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Nicoletto MO, Baldoni A, Casarin A, Randon
G, Nardin M, Baretta Z, Lardelli P, Nieto A, Alfaro V, Rigamonti C
and Conte PF: Trabectedin plus pegylated liposomal doxorubicin:
Retrospective analysis in heavily pretreated platinum-sensitive
ovarian cancer. Tumori. 101:506–510. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Araki N, Takahashi S, Sugiura H, Ueda T,
Yonemoto T, Takahashi M, Morioka H, Hiraga H, Hiruma T, Kunisada T,
et al: Retrospective inter- and intra-patient evaluation of
trabectedin after best supportive care for patients with advanced
translocation-related sarcoma after failure of standard
chemotherapy. Eur J Cancer. 56:122–130. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Tavella K, Villanucci A, Vannini L,
Lavacchi D, Montelatici S, Amunni G and Mazzei T: Stable disease in
a patient with metastatic leiomyosarcoma treated with trabectedin.
Anticancer Drugs. 28:465–468. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ledermann JA, Raja FA, Fotopoulou C,
Gonzalez-Martin A, Colombo N and Sessa C; ESMO, Guidelines Working
Group, : Newly diagnosed and relapsed epithelial ovarian carcinoma:
ESMO Clinical Practice Guidelines for diagnosis, treatment and
follow-up. Ann Oncol. 24 Suppl 6:vi24–vi32. 2013. View Article : Google Scholar : PubMed/NCBI
|
